Background/Aims: FK506 is an immunosuppressive drug and a calcineurin inhibitor that has been widely used in kidney disease in recent years. FK506 shows a wide range of biological and pharmaceutical effects; however, the mechanism of its anti-proliferative effect has not been well elucidated. An IgA nephropathy (IgAN) model was used to generate a mesangial cell proliferation model. This study aims to examine the effect of FK506 on IgAN rats and the underlying mechanisms. Methods: Hematuria, proteinuria and renal function were measured. To observe the pathological conditions, we performed HE (hematoxylin -eosin) and PAS (periodic acid -schiff) staining. Transcription and protein expression levels were detected by qRT -PCR (quantitative real-time polymerase chain reaction) and Wb (western blotting). The location and semi-quantitative expression levels of TRPCs, CaN (Calcineurin) and α-SMA were examined by IHC (Immunohistochemical staining). Results: We found that FK506 could improve hematuria, proteinuria and renal function, especially in the HF (high-dose FK506) groups. Renal pathological changes were ameliorated in the treatment groups. FK506 could significantly decrease TRPCs, CaN, phosphorylation of ERK1/2 and α-SMA expression. Conclusion: Taken together, these results suggest that the therapeutic effect of FK506 on IgAN might be partially associated with the down-regulated expression of TRPC channels, CaN and phosphorylation of ERK1/2.
Introduction
IgA nephropathy (IgAN) is the most common form of primary glomerulonephritis worldwide [1] [2] [3] , and its pathological changes are mainly depositions of IgA in the glomerular mesangial areas, often accompanied by complement C3, IgG/ IgM or both. The disease has diverse clinical and pathological features, which could lead to highly variable outcomes [3] . The clinical manifestations vary from asymptomatic microscopic hematuria with / without proteinuria to gross hematuria. Tan et al. [4] observed that 24 h urine protein levels more than 0.5 g and severe pathological lesions (> gradeⅡusing the Hass classification) are poor prognostic predictors, and patients with minimal proteinuria should also undergo renal biopsies. It is known that up to 20 -40% of patients progress to end stage renal disease within 10 years after the initial diagnostic by renal biopsy [3, 5] . Caliskan et al. [6] found that high serum uric acid levels and C3 depositions were independent risk factors in the progression of IgAN. IgAN often has mesangial cell proliferation and extracellular matrix accumulation under light microscopy [7] . Worawichawong et al. [8] showed that the EGF/ MCP-1 ratio was correlated with interstitial fibrosis and tubular atrophy, which could also act as candidate biomarkers in primary glomerulonephritis (including IgAN).
FK506 is a calcineurin inhibitor and belongs to an immunosuppressive drug class and has been widely used in kidney disease in recent years. It shares the same mechanism with cyclosporine A by inhibiting the following events. First, in combination with FK506 binding protein (FKBP12 and FKBP52), FK506 could inhibit the activity of calcineurin (CaN), Ca 2+ / calmodulin-activated phosphatase, which eventually blocks the translocation of transcription factor nuclear factor to the nucleus. Several studies have demonstrated that FK506 could inhibit the proliferation of mesangial cells and might therefore be effectively used to treat mesangial proliferative glomerulonephritis [9] [10] [11] [12] .
Calcium (Ca 2+ ) is an important signaling molecule involved in diverse cellular functions, such as cell differentiation, proliferation, migration, apoptosis and gene expression [13, 14] . Transient receptor potential canonical (TRPC) channels are voltage-independent, nonselective Ca 2+ channels [15] . The TRPC family is divided into three groups according to their sequence similarity as follows: TRPC1/4/5, TRPC2 and TRPC3/6/7. TRPC1 sometimes could also be categorized as the fourth group, independent of TRPC4/5 [16] . Several studies have reported the role of TRPC channels in cell proliferations [17] [18] [19] [20] [21] [22] [23] . All these findings indicate that TRPC channels are candidate genes for mediating cell proliferation. Only two studies have focused on human mesangial cells [20, 21] . However, little is known about the contribution of TRPC channels in observing the effect of FK506 in the proliferation of rat glomerular mesangial cells in vivo or vitro.
Mitogen-activated protein kinases (MAPKs) play a critical role in intracellular signal transduction and consist of extracellular signal-regulated protein kinase (ERK), p38 MAPK, and c-Jun N-terminal kinase (JNK) [24, 25] . The activation of ERK1/2 can transmit the extracellular stimulation signals into the nucleus and regulate gene expression, cell proliferation, differentiation, migration, invasion, apoptosis, and other biological effects [26] . A recent study found that the ERK1/2 and PKC pathways are involved in rat mesangial cell proliferation [27] . Another study by Zhuang et al. also demonstrated that the inhibition of ERK1/2 signaling via U0126 could markedly block uric acid induced rat mesangial cell proliferation [28] . Similar results were also found in an Ang II-induced glomerular mesangial cell (GMC) proliferation study, and the results revealed that p-ERK1/2 acted as an upstream signaling molecule for TRPC6 [29] . Another study showed that FK506 could activate the ERK1/2 signaling cascade in rat renal mesangial cells [30] . Previous studies have also focused on the relationships of TRPC channels and ERK1/2, though which the upstream signaling molecule remains controversial [18, 21, 22, 29, [31] [32] [33] [34] [35] . With regard to the associations between FK506 and TRPC channels, William et al. found that TRPC3, TRPC6, and TRPC7 could interact with FK506 binding protein 12 (FKBP12), whereas TRPC1,TRPC4, and TRPC5 interacts with FKBP52. These bindings of FKBP12 and FKBP52 are specific and could be displaced by the immunosuppressant drug FK506 [36] .
The model of IgAN was used in our study to generate mesangial cell proliferation through the "BSA + CCl 4 + LPS" method [37] . In this study, we observed the role of TRPC channels, CaN and ERK1/2 signaling pathways via the administration of FK506 in rats with IgAN.
Materials and Methods

Materials
FK506 was purchased from Astellas (Beijing, China). Bovine serum albumin (BSA) and lipopolysaccharide (LPS) were purchased from Sigma (St. Louis, MO, USA). Carbon tetrachloride (CCl 4 ) and castor oil were purchased from Sinopharm Chemical Reagent Co. Ltd. (Xi'an, China). Fluorescein isothiocyanate (FITC)-conjugated antibody against IgA was purchased from Sigma (St. Louis, MO, USA). Rabbit antibodies against TRPC1, TRPC4/5, TRPC3/6/7 and GAPDH were purchased from Santa Cruz Biotechnology (Dallas, TX, USA). Rabbit antibodies against CaN and TRPC6 were purchased from Cell Signaling Technology (Danvers, MA, USA). α-SMA, TRPC3 and TRPC4 were purchased from Abcam (Cambridge, MA, USA). TRPC5 was purchased from GeneTeX (San Antonio, Texas, USA). Horseradish peroxidase (HRP)-conjugated secondary antibodies were purchased from Jackson (Los Angeles, California, USA). All primers were synthesized by AuGCT (Beijing, China). TRIzol reagent (Invitrogen, Carlsbad, USA), reverse transcription kit, and SYBR Premix Ex TaqTM II green MasterMix kit were purchased from TaKaRa (Tokyo, Japan). 
Ethical approval
The animals used in our study were approved by the Institutional Animal Use and Care Committee at the Xi'an Jiaotong University (Approval Number: 2016-402). All procedures performed in studies involving animals were in accordance with the ethical standards of the Xi'an Jiaotong University.
Animal Model
Fifty healthy male Sprague-Dawley (SD) rats weighing 180-220 g were obtained from the animal center of Xi'an Jiaotong University. The animals were housed in the animal facilities of the Xi'an Jiaotong University with free access to food and water for 3 days to adapt the environment. The rats were randomly divided into 4 groups as follows: normal group (N, n = 13), IgAN group (M, n = 13), low-dose FK506 group (LF, n = 12) and high-dose FK506 group (HF, n = 12). We used the "BSA + CCl 4 + LPS" method to establish the IgAN model, and the procedures were as follows: 400 mg/kg BSA (rats were induced by gavaging every other day) for 6 weeks and 0.05 mg LPS (intravenous injection at the end of week 6) and 0.1 ml dissolved in 0.5 ml castor oil CCl 4 (subcutaneous injection weekly) for 6 weeks. The low and high dose FK506-treated groups were given 0.5 and 1.0 mg/kg/d FK506, respectively, from the end of week 6 for 2 weeks and 4 weeks to the end of 8 and 10 weeks until they were sacrificed. The normal group and the IgAN group were given the same volume of distilled water at the same time (Fig. 1 ).
Clinical and pathological evaluation
The 24 h urine was collected using metabolic cages at weeks 0, 3, 6, 8, and 10 for measuring the urinary red blood cells and 24 h urinary protein. The red blood cells were counted from 10 fields of vision at high magnification. Red blood cells ≥3 per field of vision at high magnification were considered positive for microscopic hematuria. The 24 h urine protein was measured with an automatic biochemical analyzer. Rats were anesthetized by sodium pentobarbital anesthesia. Half of the rats were sacrificed at the end of week 8, and the rest were sacrificed at the end of week 10. The urea nitrogen (BUN) and blood creatinine (sCr) were tested with full automatic biochemical analyzers using abdominal aortic blood samples. One part of the kidneys were fixed in 4% paraformaldehyde, followed by paraffin embedding. Serial 3μm sections were cut for hematoxylin and eosin (HE) staining, periodic acid -schiff (PAS) staining and immunohistochemistry (IHC). The residual kidneys were frozen in liquid nitrogen for frozen sections, immunofluorescence (IF), quantitative real-time polymerase chain reaction (qRT -PCR) and Western blotting (Wb).
Direct Immunofluorescence
The deposition of IgA was determined by direct immunofluorescence (IF) staining. For this staining, frozen renal tissues were prepared as described previously and were fixed with cold acetone for 30 min at 4°C after washing with phosphate buffered saline (PBS), blocking with 5% bovine serum albumin (BSA) and then incubating with the FITC -conjugated IgA antibody (1:1000) for 1 h at room temperature. After washing with PBS, coverslips were sealed with anti-quenching fluorescent mounting medium. The stained frozen sections were viewed under Nikon fluorescence microscopy.
qRT -PCR
The total cortical renal RNA was extracted using TRIzol reagent (Invitrogen, Carlsbad, USA) and reverse transcribed into cDNA using a Primescript TM RT reagent kit (TaKaRa, Japan), and 500 ng of total RNA was used. The qRT -PCR amplification with primers was carried out in an ABI Prism 7300 sequence detection system (Applied Biosystems, USA) using a SYBR Premix Ex Taq TM II green MasterMix (TaKaRa, Japan). GAPDH was used as an endogenous control. The corresponding primers used in our study are listed in Table 1 .
Western Blotting
The renal cortex was homogenized in RIPA buffer (Heart, Xi'an, China), and the protein concentration was measured using BCA kits (Heart, Xi'an, China). Each protein sample was run on an 8-10% SDS -PAGE gel. After electrophoresis, the proteins were electron transferred onto polyvinylidene fluoride (PVDF) membranes (Millipore, USA) for 2 hours using a Mini Trans-Blot Electrophoretic Transfer Cell (Bio -Rad, Hercules, CA, USA). Then, the membranes were blocked in 5% skim milk in PBST for 1 h at room temperature and were incubated with primary antibodies against TRPC1 (1:400), TRPC4/5 (1:200), TRPC3/6/7 (1:200), CaN (1:1000), α-SMA (1:200) and GAPDH (1:400) overnight at 4°C. After washing 3 times, the membranes were incubated with HRP -conjugated secondary antibody (1:100, 000) for 1 h at room temperature. Protein bands were visualized using an enhanced chemiluminescence detection kit (Millipore, USA). The band intensity was quantified by densitometry using ImageJ software.
Pathologic Evaluation and Immunohistochemical staining
For HE, PAS and IHC staining, 3μm sections of paraffin -embedded kidneys were prepared by a routine procedure. For IHC staining, the sections were then incubated with rabbit polyclonal anti -TRPC1 at 1:100, anti -TRPC3 goat polyclonal antibodies at 1:500, anti -TRPC4 mouse monoclonal antibodies at 1:100, rabbit anti -TRPC5 antibodies at 1:200, rabbit anti -TRPC6 at 1:100 and rabbit anti -CaN and α-SMA at 1:50. After incubation with the primary antibodies at 4°C overnight, the slides were stained with HRP-conjugated secondary antibody and DAB reagent (Zhongshan Jinqiao, Beijing). The slides were viewed under a Nikon Eclipse Microscope equipped with a digital camera (Nikon, Tokyo, Japan). Glomerular damage and mesangial proliferation were determined by examining 20 glomeruli in each sample. The results were expressed as the average number of sectioned glomerular nucleated cells. All sections were evaluated by an investigator in a blinded manner.
Statistical analysis
All data were expressed as the mean ± SD. Statistical analyses were performed using SPSS 20.0 software. Comparisons among the groups were made using one-way analysis of variance followed by t-tests. P values < 0.05 were considered statistically significant.
Results
The glomerular deposition of IgA Direct IF staining of IgA showed that the normal rat had very little deposition of IgA in the glomeruli. In contrast, the IgAN model rat had granule -like green fluorescence, although these images do not provide evidence for increased deposition in the thick loop region. Most of this fluorescence was in the glomeruli. The result indicated the successful establishment of an IgAN model (Fig. 2) .
FK506 reduced hematuria, proteinuria and improved renal function
All rats grew well and were alive before killing. As shown in Fig. 3A and 3B, the IgAN model rats had increased urinary red blood cell counts and 24 h urine protein levels from the induction of IgAN, and these indicators continued to increase at the end of 3 and 6 weeks to the end of the study compared to normal rats (P < 0.01). These effects were markedly inhibited by the administration of FK506 at the end of 8 and 10 weeks (P < 0.05 for the LF group at the end of week 8, P < 0.01 for the LF group at the end of week 10 and the HF group) versus the M group, although the rats still showed mild hematuria and proteinuria compared to the N groups. The HF groups had lower urinary red blood cell counts at the end of week 10 and lower 24 h urine protein levels compared to the LF groups (P < 0.05).
As for serum biochemical parameters, the M rats showed significantly increased serum levels of BUN (Fig. 3C) and Cr (Fig. 3D) at the end of 8 and 10 weeks compared to the N rats (P < 0.01 for both), which could be sharply inhibited after the administration of FK506 (P < 0.05 for the LF group, P < 0.01 for the HF group). The HF group rats showed much better renal function versus the LF groups (P < 0.05). In addition, the result at the end of week 10 had significant differences in the serum level compared to the end of week 8 for the LF and HF group rats (P < 0.05). However, there were no significant differences in the serum levels of BUN at the end of 8 and 10 weeks (P > 0.05).
FK506 ameliorated the structural lesions of glomeruli
As shown in Fig. 4 , HE staining indicated that the pathological changes of IgAN rats glomeruli were characterized by glomerular swelling, increased glomerular volume and number of cells in the glomeruli (M: 71.19 ± 1.03 vs. N: 37.02 ± 1.73, P < 0.01 for 8 week, and M: 71.33 ± 0.58 vs. N: 37.67 ± 1.53, P < 0.01 for 10 week). Some renal tubules showed infiltrated inflammatory cells (Fig. 4B and 4F) . The glomerular proliferation phenomenon and renal histopathology were ameliorated by treatment with FK506 (Fig. 4C, 4D and 4G, 4H, P < 0.01), especially in the HF group rats (Fig. 4D and 4H , P < 0.01). There were no significant differences in the number of cells in the glomeruli at the end of 8 and 10 weeks in the LF and HF groups (P > 0.05). As shown in Fig. 5 , PAS staining demonstrated that compared with normal animals, the IgAN rats had glomerular hypercellularity marked by mild to moderate proliferation of the mesangial cells and hyperplasia of the mesangial matrix ( Fig. 5B and 5F ). FK506 showed therapeutic effects in the IgAN rats, characterized by significantly reduced accumulation of mesangial matrix and proliferation of mesangial cells (Fig. 5C, 5D and 5G, 5H). There were no significant differences in the glomeruli between the 8 and 10weeks in the LF and HF groups. expressed in the glomeruli (including mesangial cells). However, the expressions of TRPC1 in the M groups were significantly enhanced versus the N group (P < 0.05 for the protein levels at the end of week 8, P < 0.01 for the rest, Fig. 6A -b, f and Fig. 6B ). Meanwhile, the TRPC1 expressions in the renal cortex declined in the FK506-treated groups (P < 0.05, for the protein levels at the end of week 8, P < 0.01 for the rest). There were no significant differences in the gene expression of TRPC1 between the LF and HF groups (P > 0.05). However, as shown in Fig. 6B -c, there were decreased mRNA levels at the end of week 10 compared to the end of week 8 (P < 0.05), although the protein levels had no significant differences (P > 0.05). With regard to TRPC3/6/7, as shown in Fig. 7A a, e and B a, e, the N group had lower expressions of TRPC3 and 6 in the glomeruli (including mesangial cells), whereas the M group showed increasing expressions of TRPC3 and 6, which also could be found in the tubules and interstitial areas (Fig. 7A-b, f , B-b, f and Fig. 7C , P < 0.05 for the protein levels of TRPC3 at the end of week 8 measured by IHC, P < 0.01 for the rest). Furthermore, TRPC3 and 6 expressions were down-regulated by treatment with FK506 (P < 0.05 for the protein levels at the end of week 8 by IHC and the protein level in the HF group by Wb, P < 0.01 for the rest). There were no significant differences in the gene expression levels of TRPC3 and 6 between the LF and HF groups (P > 0.05). However, as shown in Fig. 7C-c, d and f, there were decreased expression levels of TRPC6 at the end of week 10 compared to the end of week 8 (P < 0.05).
Finally, in terms of TRPC4/5, as shown in Fig. 8A and B, we found that TRPC5 had higher positive expression areas compared with TRPC4, and both of these could be seen in the glomeruli (including mesangial cells), tubules and interstitial areas. The M groups had elevated expressions of TRPC4 and 5 versus the N groups (P < 0.01, Fig. 8A -a, b and e-f, B-a, b and e-f and C). Furthermore, both the TRPC4 and 5 expressions were decreased by the administration of FK506 except for the protein expression of TRPC4/5 at the end of week 10 in the LF groups (P < 0.05, for the protein level at the end of week 10 in the HF group, P < 0.01 for the rest). No significant differences were observed between the LF and HF groups except for the protein expressions of TRPC4 examined by IHC (P < 0.01, Fig. 8C-d) . We found an interesting result that the protein levels of TRPC5 were markedly up-regulated in the HF groups at the end of week 10 in comparison with the end of week 8 (P < 0.05 for the IHC results and P < 0.01 for the Wb).
FK506 decreased Calcineurin gene expression in rats with IgAN
Next, we explored the possible involvement of CaN, because FK506 is a specific inhibitor of CaN. For this purpose, the mRNA and protein expressions of CaN in the renal cortex of IgAN rats were detected. As shown in Fig. 9A-a, b and e-f, CaN was mainly located in glomeruli (including mesangial cells). In Fig. 9B , the renal cortex expressions of CaN were significantly up-regulated in the M groups compared to the N group (P < 0.05 for the protein expression at the end of week 8 and mRNA levels, P < 0.01 for the rest). The FK506-treated groups showed decreased CaN expressions in the renal cortex (P < 0.05, for the mRNA levels at the end of There were no significant differences in the gene expression of CaN at the end of week 8 between the LF and HF groups (P > 0.05). In contrast, the HF group showed down-regulation effects compared with the LF group both in protein and mRNA levels at the end of week 10 (P < 0.01, for protein levels by Wb, P < 0.05, for mRNA and protein expressions by IHC). In addition, the mRNA and protein levels were lower at the end of week 10 versus the end of week 8 in the HF groups (P < 0.05); in the LF group, no significant differences were observed for the mRNA and protein expressions (P > 0.05).
FK506 down-regulated p-ERK1/2 protein expression in rats with IgAN
We assessed the p-ERK1/2 protein expressions by Western blotting. As shown in Fig.  10 , the M groups showed elevated protein expressions compared to the N groups (P < 0.05 at the end of week 8, P < 0.01 at the end of week 10). We also found lower expressions of p-ERK1/2 by CNI; the FK506-treated groups showed decreased protein expressions of p-ERK1/2 compared with the M groups except the LF group at the end of week 10 (P < 0.05 for the HF group at the end of week 8, P < 0.01 for the rest). The protein levels were increased at the end of week 10 versus the end of week 8 in the LF groups (P < 0.05), whereas in the HF group, no significant differences were observed (P > 0.05).
FK506 suppressed α-SMA protein expression in rats with IgAN
Glomerulosclerosis is characterized by ECM accumulation and deposition. We selected α-SMA as representative of the ECM. Western blotting and IHC staining were utilized to examine the effect of FK506 on the α-SMA expression in the renal cortex of IgAN. As demonstrated in Fig. 11A , α-SMA was expressed in the glomeruli (including mesangial cells) and tubular areas. The N group expressed a small amount of α-SMA, whereas the protein levels of α-SMA were up-regulated in the M group (P < 0.05 for Western blotting, and P < 0.01 for IHC results). α-SMA expressions were lower in the HF groups (P < 0.05), but not for the LF groups for Wb (P > 0.05), which were inconsistent with the IHC results. The IHC results showed decreasing expressions both in the LF and HF groups (P < 0.01). There was no significant difference between these two treatment groups (P > 0.05). Furthermore, the results were similar to the end of 8 and 10 weeks in both the LF and HF groups (P > 0.05).
Discussion
In our present study, to elucidate the role of TRPC channels, CaN and ERK1/2 in the pathogenesis of mesangial proliferative glomerulonephritis and to determine whether FK506 is a therapeutic target for the treatment of IgAN, we examined the effects of FK506 in rats with IgAN models. To the best of our knowledge, this is the first study of the contribution of TRPC channels in observing the effect of FK506 on IgAN in vivo. Our findings showed that FK506 could improve hematuria, proteinuria and renal function, and no side-effects were observed. However, the serum levels of BUN at the end of week 8 were slightly elevated compared with the levels at the end of week 10, although this difference did not reach statistical significance.
Our results were, at least in part, in parallel with the work by Ikezumi et al. [12] in Thy 1.1 nephritis, which was induced by an anti-Thy 1.1 monoclonal antibody. In their study, they found that no side effects were detected in the FK506 treatment groups of 0.1 and 0.3 mg/ kg/d body weight for 2 weeks. However, in the 1.0 mg/kg/d body weight groups, the serum levels of BUN were increased, which was different from our results, whereas the sCr levels were consistent with our study. With regards to the proteinuria, they found that the 0.1 mg/ kg/d group could not reduce the proteinuria, but the 0.3 and 1.0 mg/kg/d groups sharply decreased the degree of proteinuria and glomerular alteration in a dose-dependent manner, which was consistent with our results in the 0.5 and 1.0 mg/kg/d groups.
Another study by Liu et al. [38] carried out in rats with adriamycin nephropathy suggested with that the administration of 0.5 mg/kg/d and 1.0 mg/kg/d FK506 for 4 weeks, the proteinuria of 50% of rats was in complete remission in the 0.5 mg/kg/d group, and in the 1.0 mg/kg/d group, 50% of rats obtained partial remission, though the result had no significant difference. This result might be ascribed to individual differences, the severity of disease, different treatment methods, observational time, and drug absorption and metabolism.
Our results also found that TRPC4/5 channels occur in rat mesangial cells and were detected by IHC and play a pivotal role in cell proliferation using the Santa Cruz polyclonal TRPC4/5 antibodies by Western blotting, Abcam (TRPC4 antibody) and GeneTeX (TRPC5 antibody) via IHC staining, although the qRT -PCR results of the mRNA levels of TRPC4 and TRPC5 were unsatisfactory due to the low abundance. This result was somewhat inconsistent with the previous study by Goel et al. in 2005 , which stated that by using TRPCspecific, affinity-purified antibodies, only TRPC1, 3 and 6 were detectable in rat kidney, and they were unable to detect the presence of TRPC4, 5 and 7 [39] . However, there were also some similar results concerning TRPC4 and TRPC5 in the rat renal microcirculation and descending vasa recta (DVR) [40, 41] . In the first study, they stated that TRPC1, 3, 5, and 6 protein were expressed in the glomeruli [40] . The second study used qRT-PCR and revealed the mRNA expression of TRPC4, but not TRPC5 in microdissected DVR and was similar to the immunohistochemical studies that suggested the presence of TRPC4 in both endothelial cells and pericytes. We thought the specificity and selectivity of the antibodies or the using methods might cause this inconsistency.
qRT -PCR, Western blot and IHC staining demonstrated that the gene expressions of these three TRPC subtypes were all increased in IgAN rats. FK506 could inhibit the mRNA and protein levels of TRPC channels. In terms of TRPC1, we found that changes of transcription levels and proteins expressions are not in synchronicity because the mRNA levels showed a decreased tendency at the end of week 10, while the protein levels did not change. Additionally, there was no significant difference between the LF and HF groups. We think this finding might be due to translational and post-translational modifications. We also need to extend the treatment time of FK506 to observe the genuine inhibition effect of TRPC1.
As for TRPC3/6/7 and CaN, our study showed consistent result for mRNA and protein levels for TRPC6, although for TRPC3, there were no significance differences between the LF and HF groups at the end of 8 and 10 weeks. When comparisons were made between these two treatment groups, we found there was no difference about the TRPC3/6/7 levels between the LF and HF groups or at the end of 8 and 10weeks. Unlike TRPC3/6/7, the HF groups had a lower expression of CaN compared with the LF groups at the end of week 10. This result was partially consistently with the research by Liu et al. [38] , which indicated that the expression of these two indexes had no significant difference with treatment with 0.5 mg/kg/d and 1.0 mg/kg/d FK506 for 4 weeks in adriamycin nephropathy. For the inconsistency of CaN, we thought different pathological features of the model could clarify the discrepancy. Given that the TRPC3/6/7 and CaN levels were both down-regulated at the end of week 10, although the former did not reach the significant difference, there was the hypothesis that TRPC3/6/7 and CaN might be associated with the progression of the later stages diseases or chronic diseases. Additionally, there were some important discoveries revealed by these two studies. For example, a study by Roedding et al. [42] noticed that dosedependent reductions in TRPC3 protein expressions occurred after chronic but not acute rotenone treatment. Another study was carried out in patients with chronic kidney disease and stated that reduced extracellular calcium concentrations increased TRPC3 channel protein expression [43] . Therefore, we inferred that by down-regulating TRPC3/6/7 and CaN expressions, FK506 could inhibit proliferation of rat mesangial cells in later stages of diseases.
Next, we analyzed the results concerning protein expressions of TRPC4/5 and p-ERK1/2. We found that both TRPC4/5 and p-ERK1/2 protein levels were higher at the end of week 8 vs. the 10week, which was different from the tendencies of TRPC1, TRPC3/6/7 and CaN. In light of this result in our study, we postulated that TRPC5 and p-ERK1/2 might interact with each other, demonstrating functional crosstalk of both, mainly involved in early stages of the disease. This hypothesis requires further investigation and validation.
Finally, we detected the protein expressions of α-SMA. Our data indicated that it was the HF groups, not the LF groups, which reduced the protein levels of α-SMA by Wb, whether at the end of week 8 or 10. However, the IHC results revealed both treatment groups downregulated α-SMA expressions. In light of this phenomenon, we thought that different methods might cause the disparity. For example, before performing the Wb, we should homogenize part of the frozen renal cortex tissues in appropriate RIPA buffers to prepare the protein samples on ice, while the IHC staining was observed the whole longitudinal section of the renal tissues. Therefore, we thought the IHC results might more convincing. We also found that there was no significant difference between these two treatment groups; our results were partly different from the results by Ikezumi et al. [9] on Thy 1.1 nephritis. They found that all these three doses 0.3, 0.5, 1.0 mg/kg/d FK506 groups could ameliorate the expression of α-SMA on day 14. We thought these findings might boil down to different establishing methods, times, administration of the drug methods, for example, by intramuscular injection or by gavaging. Additionally, we should prolong the treatment times of FK506 to observe the true inhibition effect of α-SMA and at the same time to detect the blood drug concentrations when using it for clinical treatment.
The limitations of our study include the relatively coarse dose administration groups, that is, it would be better if we add two more FK506 treatment groups (0.3, 1.5 mg/kg/d) with prolonged treatment times. We should also detect the blood drug concentrations of FK506 to better understand the side effects. In addition, the number of rats in our study was small, and the study might not have had enough statistical power to determine real associations. Furthermore, we did not use TRPC and ERK1/2 inhibitors to observe their effects on IgAN rats, which might limit evaluation of the potential role of TRPC and ERK1/2 in the development of IgAN.
Conclusion
Our study indicates that FK506 could ameliorate IgAN through the inhibiting the expression of the TRPC channels, CaN and p-ERK1/2. These findings suggest that FK506 might be a potential therapeutic agent to prevent the progression of IgAN.
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